News
Part 1: 2010 Lecture on US Health Reform
20 July 2010
Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care…
Estimating US Savings from Biosimilars
13 July 2010
The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually…
EU Approval of Biosimilars
8 July 2010
Biosimilar products in the European Union (EU) must go through a centralised procedure that licenses the product for use in EU Member States. Until experience grows…
Reminder: Willingness-to-Pay Seminar
5 July 2010
Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money? Whose Money? During this OHE Lunchtime Seminar, Prof Peter Zweifel, University of Zurich, will discuss the findings…
Biosimilars’ Price Dynamic in Europe
30 June 2010
Europe already has some experience with the impact of biosimilars on pricing, including a price war in Germany for EPOs. Whether that experience will be repeated,…
Price Competition and Biosimilars
23 June 2010
Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
The OHE model varies from other models of biosimilar markets evolution by starting with transaction prices, rather than list prices, and factoring in the collection of…
Reminder: 2010 Lecture on US Health Reform
14 June 2010
OHE’s 2010 Annual Lecture features Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research…
EuroQol Group to Report Key EQ-5D Advances
10 June 2010
The EuroQol Group’s 27th Scientific Plenary will take place in mid-September. Researchers will report on several exciting developments in the EQ-5D, a measure of self-reported health…